Biogen Inc. buy Royal Bank of Canada
Start price
19.09.24
/
50%
€180.40
Target price
19.09.25
€262.25
Performance (%)
-36.36%
Price
10:00
€114.80
Summary
This prediction is currently active. The BUY prediction by Royal_Bank_of_Canada for Biogen Inc. is performing very badly with a performance of -36.36%. This prediction currently runs until 19.09.25. The prediction end date can be changed by Royal_Bank_of_Canada at any time. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Biogen Inc. | -1.958% | -1.958% |
| iShares Core DAX® | -0.940% | 2.343% |
| iShares Nasdaq 100 | -0.726% | 1.863% |
| iShares Nikkei 225® | -0.767% | 4.952% |
| iShares S&P 500 | -0.345% | 2.613% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Biogen Inc. diskutieren
Biogen Inc. (NASDAQ: BIIB) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $292.00 price target on the stock.
Ratings data for BIIB provided by MarketBeat